Top Tech Companies (2,055)
Don't see your company?
Create a company profile
At Sony Biotechnology, our flow cytometry and imaging products reflect our full commitment to produce and support high quality, innovative products to support advanced biomedical research. Founded in 1995, we are based in San Jose, California with affiliate offices in Japan, China and Europe. Innovation Research and Development as well as engineering teams are based in Japan. Their innovative approaches and technical know-how is incorporated into our product platforms has been recognized in patents as well as numerous technology and design awards. For example, to improve stability, our systems allow direct monitoring of particle flow status using technology originally developed for the Blu-ray disk that delivers error free performance while operating at very high speed. In conventional flow cytometers, this accuracy largely depends on skillful operators. To deliver very low noise electronics, our systems incorporate technologies that have brought pure, true sound to music. This Sony know-how reduces signal noise from the electric circuit currents to achieve very low noise electronics so that rogue signal noise does not get in the way of delivering accurate results to scientists. Importantly, our innovations also come from looking beyond the conventional made possible by constant sensing and deep study of advanced technologies for superior solutions to customer challenges. Our use of microfluidics and spectral analysis are two examples of this innovative approach to product design and development.
Surgalign Spine Technologies, Inc., a global, pure-play spine company, is focused and aligned to change and advance the science of spine care. The company designs and manufactures a broad portfolio of innovative devices and tools surgeons use to restore mobility and alleviate pain for their patients. Founded in July 2020, but with a legacy of clinically validated innovation stretching back 30 years, Surgalign invests in advancing care and elevating outcomes. Surgalign markets its products in the United States and in more than 50 countries globally through a growing network of top independent distributors. The company is headquartered in Deerfield, Ill., and has a design center in Wurmlingen, Germany. Surgalign is also a member of AdvaMed.
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
Sepax Technologies, Inc., is Delaware based leading chromatography product manufacturer and service provider specializing in biological separation areas. We offer unique ranges of HPLC columns for bioanalytical characterization and testing, as well as process media for downstream process and purification of MAb, BsAb, ADC, Proteins, AAV, VLP, DNA, RNA, and various biologic samples. Sepax has a full portfolio of beads technology platforms, linker and organic synthesis chemistry, as well protein chemistry in different stages of R&D and production pipelines to support the various needs of biopharmaceutical industry and customers. Check out our website for more information www.sepax-tech.com
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers
Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh.
Salutaris Medical Devices develops ophthalmic treatment for wet age-related macular degeneration.
Splash Pharmaceuticals is a clinical stage oncology company.
Metavention develops medical devices to help with interventional therapies for Type 2 diabetes.
Epicrop develops a revolutionary epigenetic technology for improving crop yields.
PierianDx is catalyzing global adoption of genomic sequencing in healthcare
Advancing Plant Based Medicine
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.
We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).
Podimetrics is a virtual care management company dedicated to preventing costly and deadly diabetic amputations. We provide high-risk patients our FDA-cleared SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients, and allows clinicians to achieve unparalleled outcomes - keeping vulnerable patients healthy at home and saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, MA and backed by Norwich Ventures, Scientific Health Development, Polaris Partners, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics.
A Mosaic company. Our diverse portfolio of products is backed by science and used worldwide to enhance yields, improve nutrient use efficiency, disease defense, biocontrol and abiotic stress. We’re committed to developing new soil health solutions that will provide advanced crop nutrition to customers around the globe and continue to help the world grow the food it needs.
Maravai LifeSciences enables the miracles of science and improves the human condition through its portfolio of market-leading companies and proprietary technologies. Biomedical innovation is dependent on a reliable supply of reagents in the fields of nucleic acid production and biologics safety testing. From inventive startups to many of the world's leading biopharma, vaccine, diagnostics and cell and gene therapy companies, customers turn to Maravai to solve their complex discovery challenges and help them streamline and scale from research through clinical trials. TriLink BioTechnologies is a global leader in RNA synthesis and scale up, including mRNA production, yield-enhancing proprietary CleanCap® mRNA capping technology, and CDMO services ranging from research to GMP grades. Glen Research leads in specialty reagents for DNA and RNA oligonucleotide synthesis for a broad range of applications. Cygnus Technologies developed the market for bioprocess impurity detection, process-related impurity analytics and viral clearance prior to human trials, regulatory approval and commercial release. Maravai holds a number of patents and offers innovative products and services including CleanCap®, CleanAmp®, GMPLink™, Antibody Affinity Extraction™ (AAE™), EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV™, Sterling™, Glen Pak™, Glen Gel-Pak™, Poly-Pak™. Maravai's portfolio companies are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications. Founded in 2014 and headquartered in San Diego, Maravai LifeSciences is online at www.maravai.com.
Medelis is a pharmaceutical company located in Nashville.
To use Susavion’s patented MultiValent Peptide Mimetic (MVPM) Technology platform to harness the innate power of the immune system to combat diseases with non-toxic, safe and effective treatments. At Susavion, we pride ourselves on doing things differently. We’re at the forefront of scientific innovation, leading the charge in the effort to solve some of healthcare’s most intractable problems. Our revolutionary therapy is safe and nontoxic, and we care about the people our research will benefit—always balancing our cutting-edge technology with our humanity.
